Molecular Targeting Technologies, Inc.
MTTI is a clinical stage company transforming the lives of patients with severe diseases thru innovative targeted theranostics.
EBTATE (177Lu-EB-DOTA-TATE) radiotherapeutic targets somatostatin receptors in neuroendocrine neoplasms. EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing PRRTs. EBTATE trials in 62 NET patients were well tolerated and more effective than 177Lu-DOTA-TATE at 40% of the radioactivity dosed. 3-year follow up showed 86% disease control. Trials expanding into small cell lung , Hurthle cell thyroid and nasopharyngeal cancers. Acquired under an exclusive global license from NIH.
EBRGD (177Lu-EB-DOTA-RGD) is a selective, cancer fighting radiotherapeutic targeting αvβ3-expressing tumors. Studies are currently focused on non-small cell lung cancer and glioblastoma multiforme. Acquired under an exclusive global license from NIH.
TDURA (99mTc-duramycin) radiodiagnostic targets PE, externalized in dying cells. Clinical trials imaging colorectal tumor response to chemotherapy underway.
FGA (18F-fluoroglucaric acid) radiodiagnostic targets histones to detect necrosis and apoptosis, tracking tumor response to therapy. MTTI owns a proprietary, low cost route from FDG. FGA holds promise in a range of diseases.
Our Team: Seasoned executives from multinational pharmaceutical companies, each with a successful track record.
Brands: EBTATE (177Lu-EB-DOTA-TATE)
EBRGD (177Lu-EB-DOTA-RGD)
TDURA (99mTc-duramycin)
FGA (18F-fluoroglucaric acid)